<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958711</url>
  </required_header>
  <id_info>
    <org_study_id>U-0801</org_study_id>
    <nct_id>NCT00958711</nct_id>
  </id_info>
  <brief_title>The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer</brief_title>
  <official_title>The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synovis Surgical Innovations</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synovis Surgical Innovations</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and
      compare its performance with the standard of care, saline moistened gauze, for the treatment
      of diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Budgetary
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to complete healing</measure>
    <time_frame>Day -7 (baseline), day 0, 72 hours, wk 1, wk 2, wk 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percent of wounds healed at 12 weeks</measure>
    <time_frame>Day 0, wks 1 - 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>wound healing pathway markers</measure>
    <time_frame>day 0, 72 hours, wk 1, wk 2, wk 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>bacterial burden</measure>
    <time_frame>day 0, wk 1 - 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) mean &amp; median of % wound size changes 2) ulcer recurrence 3) adverse events</measure>
    <time_frame>wk 4, wk 8, wk 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Biologic - Unite Biomatrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline and Gauze</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unite Biomatrix</intervention_name>
    <description>Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
    <arm_group_label>Biologic - Unite Biomatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline and Gauze</intervention_name>
    <description>gauze moistened with sterile saline</description>
    <arm_group_label>Saline and Gauze</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A full thickness diabetic foot ulcer with a viable wound bed free of necrotic material
             (grade 1 on Wagner scale).

          2. Diagnosis of diabetes mellitus (type I or II) adequately controlled.

          3. The ulcer is greater than 4 weeks duration.

          4. Three or fewer ulcers separated by &gt; 3.0 cm distance.

          5. Post-debridement, the ulcer size must be between 1 and 10 sq cm2.

          6. Ankle/brachial index is between 0.7 to 1.2 and or one of the following must be
             present:

               -  transcutaneous partial pressure oxygen (TcPO2) &gt; 30 mmHg at the ankle

               -  toe pressure of &gt;40mm Hg or a Doppler waveform consistent with adequate flow in
                  the foot (biphasic or triphasic)

          7. At least 18 years old.

          8. Able and willing to provide a voluntary written informed consent.

          9. Able and willing to wear an off-loading orthopedic shoe.

         10. Able and willing to attend scheduled follow-up visits and study related exams.

        Exclusion Criteria:

          1. Greater than 30% reduction in wound size during first week of observation by the
             investigator.

          2. Ulcer with exposed tendon or bone.

          3. Gross clinical infection at the study ulcer site including cellulitis and
             osteomyelitis.

          4. Gangrene.

          5. Active Charcot's disease as determined by clinical and radiographic examination.

          6. Ulcer of a non-diabetic pathophysiology (e.g., rheumatoid, radiation-related, and
             vasculitis related ulcers).

          7. Known severe anemia.

          8. Known serum albumin &lt; 2.5.

          9. Renal failure with Creatinine &gt; 2.5.

         10. Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell
             disease, HIV.

         11. Severe liver disease as defined by the treating physician or patient's primary care
             physician.

         12. Malignancy at or near the ulcer site.

         13. Any condition judged by the investigator that would cause the study to be detrimental
             to the patient.

         14. Presence of a hematology, clinical, chemistry or other test obtained within 7 days of
             screening that is outside the normal range for the laboratory and is determined to be
             clinically significant by the investigator.

         15. Received another investigational device or drug within 30 days of Day 0.

         16. Radiation therapy, chemotherapy or immunosuppressive therapy within 30 days of
             enrollment.

         17. Received another allograft, autograft or xenograft within 30 days of the Day 0.

         18. Known allergy to equine derived tissue.

         19. Alcohol or drug abuse, defined as current medical treatment for substance abuse.

         20. Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiyan Diabetes Center</name>
      <address>
        <city>Evans</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot &amp; Ankle Associates of Central Illinois, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Foot and Ankle</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle East</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina East Family Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Foot &amp; Ankle Physicians</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Wound Care Thoracic &amp; Vascular Associates of Kinston P.A.</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Foot &amp; Ankle Associates of North Carolina, PLLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

